Bank of America Issues Pessimistic Forecast for Kura Oncology (NASDAQ:KURA) Stock Price

Kura Oncology (NASDAQ:KURA) had its price target decreased by analysts at Bank of America from $36.00 to $29.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Bank of America‘s target price would suggest a potential upside of 189.97% from the company’s current price.

A number of other equities analysts have also weighed in on the company. Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Thursday. Jefferies Financial Group reduced their price target on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday. JMP Securities restated a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Tuesday. Finally, UBS Group began coverage on Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $29.38.

Kura Oncology Stock Performance

Shares of NASDAQ KURA opened at $10.00 on Friday. The stock has a market cap of $777.72 million, a PE ratio of -4.24 and a beta of 0.86. Kura Oncology has a 1 year low of $9.06 and a 1 year high of $24.17. The firm has a fifty day moving average price of $18.28 and a 200-day moving average price of $19.82. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Hedge Funds Weigh In On Kura Oncology

Several large investors have recently modified their holdings of KURA. Suvretta Capital Management LLC grew its holdings in Kura Oncology by 8.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock valued at $149,535,000 after purchasing an additional 583,155 shares during the last quarter. Vanguard Group Inc. increased its holdings in Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after purchasing an additional 28,212 shares during the period. Armistice Capital LLC raised its holdings in shares of Kura Oncology by 14.7% in the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after acquiring an additional 302,000 shares in the last quarter. Artal Group S.A. lifted its stake in Kura Oncology by 8.6% in the first quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock worth $40,951,000 after acquiring an additional 151,828 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Kura Oncology by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock worth $34,798,000 after acquiring an additional 41,535 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.